Biohaven (BHVN) Total Current Liabilities (2021 - 2026)
Biohaven (BHVN) reported Total Current Liabilities of $52.1 million for Q1 2026, down 68.25% on a YoY basis from $164.0 million in Q1 2025, and down 55.08% sequentially from $115.9 million in Q4 2025.
Biohaven (BHVN) Total Current Liabilities (2021 - 2026) Analysis & Trends
Biohaven (BHVN) has 6 years of Total Current Liabilities data on file, last reported at $52.1 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities fell 68.25% year-over-year to $52.1 million; the trailing twelve-month figure through Mar 2026 stood at $52.1 million (down 68.25% YoY), and the FY2025 full-year result was $115.9 million, down 24.83% from the prior year.
- Total Current Liabilities eased to $52.1 million in Q1 2026, from $115.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $164.0 million in Q1 2025 to a low of $28.4 million in Q3 2022.
- A 5-year average of $103.8 million and a median of $113.0 million in 2025 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities surged 178.27% in 2024 and slumped 68.25% in 2026, its largest moves.
- Tracing BHVN's Total Current Liabilities over 5 years: stood at $90.0 million in 2022, then sank by 38.43% to $55.4 million in 2023, then surged by 178.27% to $154.2 million in 2024, then retreated by 24.83% to $115.9 million in 2025, then slumped by 55.08% to $52.1 million in 2026.
- Business Quant data shows BHVN's Total Current Liabilities at $52.1 million in Q1 2026, $115.9 million in Q4 2025, and $113.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Biohaven | 2.16 Bn | 1.81 Bn | - | 52.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52.08 Mn |
| Dec 31, 2025 | 115.93 Mn |
| Sep 30, 2025 | 113.02 Mn |
| Jun 30, 2025 | 124.32 Mn |
| Mar 31, 2025 | 164.03 Mn |
| Dec 31, 2024 | 154.23 Mn |
| Sep 30, 2024 | 152.29 Mn |
| Jun 30, 2024 | 156.21 Mn |
| Mar 31, 2024 | 86.59 Mn |
| Dec 31, 2023 | 55.42 Mn |
| Sep 30, 2023 | 62.18 Mn |
| Jun 30, 2023 | 87.85 Mn |
| Mar 31, 2023 | 114.01 Mn |
| Dec 31, 2022 | 90.02 Mn |
| Sep 30, 2022 | 28.44 Mn |
| Dec 31, 2021 | 41.94 Mn |